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The neurological involvement in acute liver failure (ALF) is characterized by arousal
impairment with progression to coma. There is a growing body of evidence that neuroin-Available online 11 July 2014
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ﬂammatory mechanisms play a role in this process, including production of inﬂammatory
cytokines and microglial activation. However, it is still uncertain whether brain-derived
cytokines and glial cells are crucial to the pathophysiology of ALF at the early stage, before
coma development. Here, we investigated the inﬂuence of cytokines and microglia in ALF-
induced encephalopathy in mice as soon as neurological symptoms were identiﬁable.
Behavior was assessed at 12, 24, 36 and 48 h post-injection of thioacetamide, a hepatotoxic
drug, through locomotor activity by an open ﬁeld test. Brain concentration of cytokines
(TNF-α and IL-1β) and chemokines (CXCL1, CCL2, CCL3 and CCL5) were assessed by ELISA.
Microglial activation in brain sections was investigated through immunohistochemistry,
and cellular ultrastructural changes were observed by transmission electron microscopy.
We found that ALF-induced animals presented a signiﬁcant decrease in locomotor activity
at 24 h, which was accompanied by an increase in IL-1β, CXCL1, CCL2, CCL3 and CCL5 in the
brain. TNF-α level was signiﬁcantly increased only at 36 h. Despite marked morphological
changes in astrocytes and brain endothelial cells, no microglial activation was observed.1
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b r a i n r e s e a r c h 1 5 7 8 ( 2 0 1 4 ) 4 9 – 5 950These ﬁndings suggest an involvement of brain-derived chemokines and IL-1β in early
pathophysiology of ALF by a mechanism independent of microglial activation.
& 2014 Elsevier B.V. All rights reserved.1. IntroductionAcute liver failure (ALF) is a rare but severe clinical syndrome
deﬁned by a sudden loss of hepatic function and the presence
of increased circulating levels of liver enzymes, coagulopathy
and overt encephalopathy (Bernal et al., 2010). The neurolo-
gical involvement in ALF is characterized by a rapid progres-
sion of arousal impairment from mild lethargy and confusion
to stupor and coma (Shawcross and Wendon, 2012). Hepatic
encephalopathy is one of the major complications and causes
of death in ALF, and arrives from brain edema, intracranial
hypertension and cerebral herniation (Bernal et al., 2013;
Vaquero et al., 2003a). The mortality rate in ALF is about
30% and might be higher if intracranial hypertension is
present. In addition, severe intracranial hypertension may
also preclude emergency liver transplantation, the only
deﬁnitive treatment available (Bernal et al., 2013). A better
understanding of the physiopathology of ALF and the related
encephalopathy is crucial for the development of new thera-
pies that would slow down its progression and improve
clinical outcome.
Encephalopathy in ALF has been considered a primary
gliopathy characterized by perivascular swollen astrocytes
end-feet leading to cytotoxic cerebral edema (Butterworth,
2012; Kato et al., 1992). The genesis of astrocyte cellular
edema is not completely understood, but the accumulation
of ammonia due to hepatic dysfunction is considered a
hallmark of its pathogenesis (Norenberg et al., 2007). More
recently a growing body of evidence has suggested that both
peripheral and central nervous system inﬂammation may
have a role in hepatic encephalopathy, acting alone or
synergistically with ammonia (Butterworth, 2011, 2013).
A signiﬁcant correlation between the severity of systemic
inﬂammatory response (resulting from hepatocyte cell death
and/or infection) and the progression of ALF-induced ence-
phalopathy has been consistently reported in experimental
models and humans (Rolando et al., 2000; Vaquero et al.,
2003b; Wright et al., 2007). Serum levels of TNF-α were found
increased in ALF patients and were positively correlated with
intracranial hypertension, a clinical condition associated
with a poor prognosis (Streetz et al., 2000; Wright et al.,
2007). The deletion of TNF-α receptor 1 (p55) delayed the
onset of coma in ALF induced by the hepatotoxic drug
azoxymethane in mice (Bémeur et al., 2010a). In this same
model, Chastre et al. (2012) demonstrated that the pretreat-
ment with etanercept (a TNF-α neutralizing molecule com-
posed of the soluble TNF-α receptor 2 – p75 – fused to the FC
portion of IgG) reduced both peripheral and cerebral inﬂam-
mation leading to delayed progression of hepatic encephalo-
pathy. Other cytokines such as IL-1α and IL-6 have also
been implicated in hepatic encephalopathy, and were found
elevated in the brain following ALF (revised in Butterworth,2013). Besides the increased levels of cytokines in the brain,
the activation of microglial cells was demonstrated in experi-
mental models of ALF resulting from hepatic devasculariza-
tion or azoxymethane (Bémeur et al., 2010b; Jiang et al.,
2009b). Microglial cells are the brain's innate immune cells
that once activated take on an ameboid appearance secreting
a range of inﬂammatory cytokines (Ransohoff and Cardona,
2010). Interestingly, microglial activation was demonstrated
to occur at fairly late stages of hepatic encephalopathy,
suggesting that other cell types could be an earlier source of
cytokines (Rangroo-Thrane et al., 2012).
The understanding of the contribution of glial cells and
brain-derived inﬂammatory cytokines at the early stage of the
pathogenesis of ALF-induced encephalopathy may provide
insights to the development of strategies to halt its develop-
ment or progression. Here, we investigated the involvement of
cerebral cytokines and chemokines, and of microglial activation
at the early stage of hepatic encephalopathy in mice. The
thioacetamide (TAA)-treated mouse model of ALF was used in
this study. This model is widely used, and is well established
relative to liver function, brain edema development and neu-
rological status, resembling several pathophysiological and
clinical features of the ALF in humans (Jayakumar et al., 2014;
Rama Rao et al., 2014; Shmarakov et al., 2014).2. Results
2.1. TAA injection promoted a decrease on locomotor
activity at different time-points
In order to detect the ﬁrst signs of symptoms in TAA-treated
mice, locomotor activity was assessed in different time points
(12, 24, 36 and 48 h) after injection of TAA. TAA decreased
locomotor activity, compared to saline administration [F(4,34)¼
6.57, po0.001], and the most signiﬁcant effect was observed at
24 h (po0.001) (Fig. 1).2.2. Effect of TAA on liver morphology and hepatic
function at 24 h post-injection
TAA is a widely recognized hepatotoxic drug. Once in circula-
tion, TAA is absorbed and bioactivated by hepatocytes. The
accumulation of toxic metabolites will ﬁnally modify amine-
lipids and proteins, causing cell damage and death in the
liver (Hajovsky et al., 2012). Here we assessed liver injury and
hepatic function at 24 h post TAA administration to study the
temporal correlation between ALF and impairment of loco-
motor activity.
Histological analysis revealed that TAA injection induced
centrilobular necrosis and hydropic degeneration in TAA-
treated mice compared with controls (Fig. 2A and B). Liver
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6.836, po0.001] (Fig. 2C), and prolonged prothrombin and
activated partial thromboplastin times [t(9)¼3.015, p¼0.014
and t(9)¼2.751, p¼0.022, respectively) (Fig. 2D and E).
As described elsewhere, increase in serum levels of
ammonia, mild brain edema and EEG changes compatible
with metabolic encephalopathy followed TAA injection in
mice (Gomides et al., 2014). Besides liver injury and brain
compromise, TAA treatment was associated with lung injury
(i.e. increased cellularity, alveolar edema and hemorrhage).2.3. Ultrastructural alterations in the brain at 24 h post-
induction of ALF
In order to evaluate the occurrence of subcellular changes in
the brain in parallel with the development of ALF, we carriedFig. 2 – Effect of TAA on liver injury and hepatic function 24 h a
histologically normal liver of control animal and (B) liver from a
multifocal areas of necrosis and degeneration. TAA-treated mice
and (E) activated partial thromboplastin time, compared with con
po0.05, (***) po0.001; unpaired Student's t-test.
Fig. 1 – Effect of TAA injection on locomotor activity. Mice were
divided in ﬁve independent groups and locomotor activity
assessed for 5min. A signiﬁcant decrease of activity (distance
walked) was observed at 24, 36 and 48 h after TAA. Results are
expressed as mean7SEM, all NZ7, (*) po0.05, (**) po0.01, (***)
po0.001; one-way ANOVA with Tukey's post hoc test.out an ultrastructural study in mouse brain following
TAA injection. Transmission electron microscopy revealed
morphological abnormalities in the brain capillaries in all
samples. Reactive endothelial cells with cytoplasmic projec-
tions and enlargement of perivascular astrocyte end-feet
were observed in ALF-induced mice compared with controls
(Fig. 3A–D). Also, swollen mitochondria and intracellular
vacuoles were observed in glial cells of TAA-treated mice
(Fig. 3E and F). Representative areas were chosen for the
ﬁgures.
2.4. Effects of TAA on serum and brain TNF-α, CXCL1 and
CCL3 levels in 24, 36 and 48 h after TAA
Serum levels of TNF-α, CXCL1 and CCL3 were assessed 24, 36
and 48 h after TAA administration. TNF-α [F(3,12)¼17.70,
po0.001], CXCL1 [F(3,12)¼5.377, p¼0.014] and CCL3 [F(3,12)¼
7.364, p¼0.0047] were signiﬁcantly increased in TAA-treated
mice in comparison with controls (Fig. 4A–C). Serum TNF-α
level was higher 36 and 48 h post TAA compared with
controls (po0.001). CXCL1 and CCL3 were higher 48 h post
TAA compared with controls (po0.01).
Brain levels of TNF-α, IL-1β, CXCL1, CCL2, CCL3 and CCL5
were measured at the same time-points, i.e. 24, 36 and 48 h
after TAA administration. TNF-α [F(3,20)¼3.603, p¼0.031],
IL-1β [F(3,20)¼4.366, p¼0.016], CXCL1 [F(3,20)¼9.221, p¼0.0005],
CCL2 [F(3,20)¼12.49, po0.0001], CCL3 [F(3,20)¼6.518, p¼0.003]
and CCL5 [F(3,20)¼11.45, p¼0.0001] were signiﬁcantly
increased after TAA administration (Fig. 5A–F). There was
an increase in TNF-α level at 36 h (po0.05), whereas IL-1β was
increased at 24 h post TAA. The higher concentrations of
chemokines CXCL1 (po0.01), CCL2 (po0.001), CCL3 (po0.01)
and CCL5 (po0.001) were reached following 24 h of TAA. Nofter drug administration. Representative sections from (A) a
mouse with acute liver failure induced by TAA, showing
presented (C) elevated serum ALT, (D) increased prothrombin
trol values. Results are expressed as mean7SEM, all NZ5, (*)
Fig. 3 – Ultra-structural changes in the brain of ALF-induced mice. Representative electron micrographs from the cortex
of (A and C) saline-treated control and (B, D and F) TAA-treated mice (N¼3). TAA-treated mice show reactive brain endothelial
cells with cytoplasmic projections (arrowhead), enlargement of astrocyte end-feet (black arrow), perivascular swollen
mitochondria (white arrow) and cellular vacuolization (asterisk), compared with control. C – blood capillary.
Fig. 4 – Analysis of serum cytokines and chemokines at different time points (24, 36 and 48 h) after TAA administration.
(A) TNF-α, (B) CXCL1 and (C) CCL3 serum levels in acute liver failure-induced mice compared with saline-treated controls.
Results are expressed as mean7SEM, N¼4, (**) po0.01, (***) po0.001; one-way ANOVA with Tukey's post hoc test.
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Fig. 5 – Analysis of brain-derived cytokines and chemokines at different time points (24, 36 and 48 h) after TAA
administration. (A) TNF-α, (B) IL-1β, (C) CXCL1, (D) CCL2, (E) CCL3 and (F) CCL5 brain levels in acute liver failure-induced mice
compared with saline-treated control. Results are expressed as mean7SEM, N¼6, (*) po0.05, (**) po0.01, (***) po0.001; one-
way ANOVA with Tukey's post hoc test.
Fig. 6 – Evaluation of leukocyte–endothelium interactions by intravital microscopy, showing (A) leukocyte rolling and (B)
leukocyte adhesion in the brain microvasculature of TAA-treated mice at different time points (24, 36 and 48 h) after drug
administration, and control group. Results are expressed as mean7SEM, NZ4; one-way ANOVA with Tukey's post hoc test.
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cytokine or chemokine at 48 h post TAA.
2.5. Leukocyte recruitment to pial microvasculature at 24,
36 and 48 h after induction of ALF
Upon activation endothelial cells can express adhesion mole-
cules and chemoattractants that are presented on their
luminal surface, leading to leukocyte–endothelium interac-
tions. Since electron microscopic analysis revealed reactive
brain endothelial cells with cytoplasmic projections to the
capillary lumen concomitant with an increase of cytokines
and chemokines expression in the brain, we assessed leuko-
cyte–endothelium interactions at 24, 36 and 48 h post TAA.
Intravital microscopy of pial microvasculature revealed sig-
niﬁcant increase in leukocyte rolling at 48 h in TAA-treated
mice compared with controls [F(3,15)¼19.16, po0.0001]
(Fig. 6A). There was also increased leukocyte adhesion, butno statistical signiﬁcance was observed [F(3,15)¼2.095,
p¼0.14] (Fig. 6B). These data provide functional evidence of
endothelial cells activation, and are also in line with the lack
of leukocyte recruitment into the brain of ALF mice.
2.6. Iba-1 expression and cellular density in the brain
at 24 and 36 h after induction of ALF
Iba-1 is a calcium-binding protein speciﬁcally expressed
in microglia in the brain. Antibodies against Iba-1 are
helpful to identify microglia with details of their processes
(Kettenmann et al., 2011). Here, we did not observe any sign
of activation of microglia either at 24 or at 36 h post TAA.
There was no increase in cellular density in ALF-induced
mice compared with controls [F(2,11)¼1.188, p¼0.341] (Fig. 7A
and B). Besides, no morphological differences were observed
between the groups. Microglia presented spindle-shaped cell
bodies and numerous long, thin, branched processes (Fig. 7C).
Fig. 7 – Effect of acute liver failure in microglial activation 24 and 36 h after TAA administration. Representative micrographs
showing the effect of acute liver failure on Iba-1 staining in (A and B) cellular density and (C) microglia morphology in the
brain of TAA-treated mice and saline-treated control. (B) Cellular density was quantiﬁed and no statistically signiﬁcant
difference was observed. Results are expressed as mean7SEM, NZ4; one-way ANOVA with Tukey's post hoc test.
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in TAA-treated mice
In order to evaluate if there was any alteration in the redox
state of the brain of TAA-treated mice in parallel with
cytokines and chemokines up-regulation, we measured the
presence of lipid peroxidation and the activity of antioxidant
enzymes 24 h after TAA administration. We observed signiﬁ-
cant decrease in activity of SOD [t(4)¼2.824, p¼0.047], GSH-Px
[t(5)¼3.448, p¼0.018] and catalase [t(4)¼2.885, p¼0.044] when
compared to controls (Supplementary Fig. 1A–C). There was
increased lipid peroxidation but statistical signiﬁcance was
not attained [t(2)¼3.758, p¼0.064] (Supplementary Fig. 1D).3. Discussion
We demonstrated that up-regulation of cytokines and che-
mokines in the brain is associated with the development of
symptoms in TAA-treated mice. Locomotor activity is a
clinical parameter widely used to stratify the severity of
hepatic encephalopathy in experimental models (Ahboucha
et al., 2008; Chang et al., 2011; Rodrigo et al., 2010). Accord-
ingly, locomotor activity was used to determine the most
appropriate time to investigate early clinical manifestations
of ALF. At 24 h, TAA-treated mice presented both the ﬁrst and
most signiﬁcant decrease in locomotor activity in parallel
with overt ALF, with increased serum levels of ammonia and
liver enzymes, coagulopathy and morphological changes in
astrocytes, conﬁrming the development of ALF-induced ence-
phalopathy. We observed that the emergence of symptoms of
ALF-induced encephalopathy preceded an increase in TNF-α
level, but IL-1β and chemokine levels were increased in the
brain 24 h after TAA administration. These data suggest
that, in the current model, the generation of IL-1β in thebrain may precede that of TNF-α leading to locomotor activity
impairment.
TNF-α and IL-1β are strongly related to the severity of
encephalopathy in a context of ALF, and interventions that
are able to block both cytokines effects in experimental
models resulted in signiﬁcantly delay in the onset of coma
and improved clinical outcomes (Bémeur et al., 2010a,b;
Chastre et al., 2012; Jiang et al., 2009b). Accordingly, IL-1β
receptor knockout mice had a delayed onset of coma in
azoxymethane-induced ALF encephalopathy, which was also
reported in mice lacking the TNF-α receptor (Bémeur et al.,
2010a,b). Besides, hepatic devascularized rats had no eleva-
tion of IL-1β or TNF-α during the asymptomatic phase, but
both cytokines were increased when rats rapidly reached the
coma stage (Jiang et al., 2009a,b).
In our model, we observed a mortality rate about 40%
between 24 and 48 h after TAA injection (Miranda et al., 2010),
while other models of ALF with encephalopathy present a
more severe course with onset of coma at approximately
14–20 h after induction of ALF with 100% of mortality (Bémeur
et al., 2010a,b; Chastre et al., 2012; Jiang et al., 2009a, b). The
prolonged course of the current model allowed the observa-
tion of the earlier elevation of IL-1β in relation to TNF-α.
In line with this ﬁnding, cultured astrocytes exposed to
ammonium chloride were able to increase mRNA for IL-1β
while those for TNF-α remained unchanged (Zemtsova et al.,
2011). Moreover, while the elevation of both IL-1β and TNF-α
in the brain after LPS may determine locomotor activity
impairment, mice lacking IL-1β converting enzyme exhibited
protection from the cerebral effects of LPS without increasing
TNF-α expression and with normal mobility in the forced
swimming test (Lawson et al., 2013).
We also found that the chemokines CXCL1, CCL2, CCL3
and CCL5 were increased in the symptomatic phase of our
model. To the best of our knowledge, this is the ﬁrst report of
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phalopathy associated with ALF. Chemokines are involved in
several neuroinﬂammatory conditions and can be produced
by different cell types including astrocytes, microglia, neu-
rons and brain endothelial cells. Recent studies have reported
an increase in the brain levels of CXCL1, CCL2, CCL3 and CCL5
in parallel with behavior impairment in different experimen-
tal models in mice (Amaral et al., 2011; Comim et al., 2011;
Pedroso et al., 2013).
The chemokine CCL2 seems to regulate the production
of inﬂammatory cytokines in the brain (Semple et al., 2010;
Strecker et al., 2011; Thompson et al., 2008). In an animal
model of seizure, an increase in the expression of CXCL1 and
CCL3 by neurons, brain endothelial cells and microglia pre-
ceded neutrophil inﬁltration (Johnson et al., 2011). In ALF, the
participation of granulocytes is not usual and not expected
(Butterworth, 2012) and, in our model, we did not observe any
leukocyte inﬁltration in the brain. Accordingly, we suggest
that CXCL1 and CCL3 may exert their actions on brain-
resident cells, rather than attracting circulating peripheral
leukocytes. In support of this, a previous study showed that
CXCL1 induced the production of CCL2, CCL3, CCL5 and TNF-α
in mice cultured astrocytes (Luo et al., 2000). Additionally,
recent studies reported that chemokines are also capable of
modulating neuronal network activity and CCL2 seemed to be
able to enhance GABA-evoked currents or by acting on the
properties of sodium channels (Belkouch et al., 2011; Caioli
et al., 2013). Previous studies have demonstrated that in ALF-
induced encephalopathy there is a neuronal dysfunction with
increased activation of NMDA receptor and its blockade was
associated with a signiﬁcant increase in survival rate (Cauli
et al., 2008). Although most authors advocate that NMDA
activation might be caused mainly by ammonia, the role
of chemokines has not been investigated yet (Hermenegildo
et al., 2000; Schwarz et al., 2012). Interestingly, chronic
exposure of cultured hippocampal neurons to CCL3 increased
NMDA-evoked signals and NMDA receptors levels (Kuijpers
et al., 2010).
The major source of cerebral cytokines and chemokines in
ALF remains to be elucidated. Jiang et al. (2009b) reported that
the use of minocycline prevented microglial activation and
TNF-α elevation in the brain of rats with devascularized liver,
slowing the development of coma. Nevertheless, the admin-
istration of a TNF-α inhibitor to mice with drug-induced ALF
prevented microglial activation, indicating a key role for TNF-
α in the activation of microglia and that this cytokine would
be produced earlier by another cell type (Chastre et al., 2012).
Here, we did not observe any morphological change in
microglia or increase in cellular density using Iba-1 staining,
suggesting that there was no overt microglial activation.
Rangroo-Thrane et al. (2012) reported microglial activation
only at a late stage in mice with toxic ALF-induced encepha-
lopathy, when animals developed signiﬁcant cerebral edema.
Hence, astrocytes, brain endothelial cells or neurons might be
involved in inﬂammatory cytokines upregulation at an early
stage of ALF preceding microglia activation.
In fact, we observed cellular ultrastructural changes of
enlarged astrocytes with mithocondrial swelling. Although
cytokines and chemokines production by these cells have
been poorly investigated, it is well-known that astrocytesexert a major role in the physiopathology of ALF through
mithocondrial dysfunction and oxidative and nitrosative
stress (Görg et al., 2008; Jayakumar et al., 2004; Rama Rao
et al., 2005). Moreover, Alvarez et al. (2011) observed that
exposition of cultured astrocytes to inﬂammatory cytokines
enhanced mithocondrial oxidative stress induction and vice-
versa, suggesting a synergic effect of these molecules. We
also observed enhanced oxidative stress in the brain, but it
remains to be determined whether astrocytes are the main
responsible for this ﬁnding.
Brain endothelial cells were shown to promote astrocyte
swelling when exposed to ammonia, LPS and inﬂammatory
cytokine mixture in vitro via oxidative and nitrosative stress
suggesting a role for them in ALF (Jayakumar et al., 2012). We
observed numerous cytoplasmic projections on brain endothelial
cells of TAA-treated mice in parallel with increased leukocyte–
endothelium interaction, a process dependent on the expression
of surface adhesion molecules and chemokines (Langer and
Chavakis, 2009). These ﬁndings suggest an early activation of
brain endothelial cells that could contribute to the pathogenic
mechanisms underlying behavioral changes in our model,
including the production of IL-1β and other cytokines and
chemokines. In this line, Jayakumar et al. (2014) demonstrated
that brain endothelial cells signiﬁcantly contributed to astrocyte
swelling and, therefore, to brain edema in the TAA-induced ALF.
Our study has several limitations. It is largely descriptive,
not investigating potential mechanisms of cytokine/chemo-
kine effects on hepatic encephalopathy. The source of these
inﬂammatory molecules in the brain during the early phase
of hepatic encephalopathy also remains to be determined in
the current and other experimental models of ALF. Besides
the liver and the brain, other organs (e.g. kidney) can be
affected by TAA treatment which was not assessed. This
issue and a potential direct effect of TAA on the brain must be
investigated in further studies. Conversely, the current study
used an established model of ALF, providing original data on
the involvement of inﬂammation in hepatic encephalopathy,
notably the participation of chemokines.
In conclusion, we observed that brain-derived inﬂamma-
tory cytokines and chemokines are involved in symptoms
emergence in ALF, independent of microglial activation.
Furthermore astrocytes and endothelial cells are candidates
for early players in the physiopathology of ALF associated
encephalopathy.4. Experimental procedures
4.1. Animals and drugs
Eight to twelve week-old, 20–25 g, female C57BL/6 mice were
obtained from the Animal Care Facilities of the Institute of
Biological Sciences, Universidade Federal de Minas Gerais.
Animals were housed in cages in temperature-controlled
rooms and received food and water ad libitum. All experi-
ments were approved by the Animal Ethics Committee of
the UFMG.
Drugs: thioacetamide (TAA; Sigma-Aldrich, St. Louis, MO,
USA) was diluted in sodium chloride 0.9% to a concentration
of 40 mg/ml.
b r a i n r e s e a r c h 1 5 7 8 ( 2 0 1 4 ) 4 9 – 5 956Acute liver failure induction: ALF was induced by intra-
peritoneal injection of a single dose of 600 mg/kg of TAA.
Sodium chloride 0.9% was given as control. All volumes
injected were calculated based on each animal weight. To
avoid hypoglycemia and dehydration, all animals received
500 μl of sodium chloride 0.9% plus glucose 5% via subcuta-
neous injection at the moment of TAA administration and
every 24 h post-injection. Temperature was maintained using
heat pads. At different time-points after TAA, mice were
anesthetized (xylazine 10 mg/kg, ketamine 100 mg/kg) and
killed for collection of blood, liver and brain samples.4.2. Open ﬁeld test
Open ﬁeld (Insight Ltda., Ribeirão Preto, SP, Brazil) test was
performed as previously described by Hall (1934) and con-
ducted in order to evaluate locomotor activity. Brieﬂy, ani-
mals were gently placed in the center of a circular plexiglass
arena (30 cm diameter) and left to explore the area for 5 min.
Total distance traveled during open-ﬁeld activity was auto-
matically analyzed by the ANY-mazes video-tracking soft-
ware (Stoelting Co., Wood Dale, IL, USA).4.3. Liver histological analysis
Livers were collected 24 h after induction of ALF and ﬁxed by
overnight immersion in 10% buffered formalin. Parafﬁn-
embedded specimens were prepared and 5.0 μm sections
were stained with hematoxylin and eosin (H&E) according
to a standard protocol. Liver pathology was assessed by an
investigator who was blinded to the experimental treatment
groups in an Olympus BX51 microscope (Center Valley,
PA, USA).4.4. Alanine aminotransferase assay
The enzyme alanine aminotransferase (ALT) is normally
present in the cytoplasm of hepatocytes and increased
activity of this enzyme in serum has high speciﬁcity as a
marker for liver damage. In order to determine the activity of
ALT, blood samples were centrifuged at 10,000 g for 15 min
at 4 1C and the supernatant was collected. Assays were
carried out with a kinetic kit (Bioclin Quibasa, Belo Horizonte,
MG, Brazil) following the manufacturer's protocol. Brieﬂy,
ALT activity is measured by monitoring the rate of NADH
oxidation in a coupled reaction system employing lactate
dehydrogenase. The oxidation of NADH to NADþ is accom-
panied by a decrease in absorbance at 340 nm.4.5. Activated partial thromboplastin time
Citrate-anticoagulated mouse plasma (50 μl) was mixed with
100 μl Dades Actin reagent (Siemens Healthcare Diagnostics
Inc., Tarrytown, NY, USA). After a 2-minute preincubation at
37 1C, 50 μl of 0.02 M CaCl2 was added and the clotting time
was determined.4.6. Prothrombin time
Citrate-anticoagulated mouse plasma (50 μl) was warmed to
37 1C for 1 min and then mixed with 200 μl Thromborel S with
calcium (Siemens Healthcare Diagnostics Inc., Tarrytown, NY,
USA) and the clotting time was determined.
4.7. Transmision electron microscopy
The animals were fully anesthetized and submitted to trans-
cardiac perfusion with saline followed by 2.5% glutaralde-
hyde/4% paraphormaldehyde in 0.1 M phosphate buffer (pH
7.4). Frontal cerebral cortex was removed and immersed in
the same ﬁxative solution overnight at room temperature.
Small brain fragments were routinely processed for Epon
embedding. Ultrathin sections were contrasted with lead
citrate and examined in Biotwin Tecnai G2-12 transmission
electron microscope at 80 keV by an investigator who was
blinded to the experimental treatment groups.
4.8. Serum and brain cytokines and chemokines
measurement
To perform the ELISA assay, the right frontal lobe of the brain
was homogenized in extraction solution containing aproti-
nin. The concentration of cytokines (TNF-α, IL-1β) and che-
mokines (CXCL1, CCL2, CCL3 and CCL5) was determined by
ELISA (R&D Systems, Minneapolis, MN, USA) following the
manufacturer's procedures. In addition, blood samples were
obtained and centrifuged at 10,000 g for 15 min at 4 1C. The
supernatant was collected for determination of cytokine TNF-
α and chemokines CXCL1 and CCL3.
4.9. Intravital microscopy
Intravital microscopy of the cerebral microvasculature
was performed as previously described (Teixeira et al., 2010;
Vilela et al., 2008). Brieﬂy, treated and non-treated mice
were cannulated for the intravenous administration of rho-
damine 6G (0.3 mg/kg; Sigma, St. Louis, MO, USA) and dura
matter removed to expose the underlying pial vasculature.
Leukocyte–endothelium interactions were visualized using
an Olympus (Center Valley, PA, USA) model BX40 microscope
ﬁtted with a ﬂuorescent light source (epi-illumination at 510–
560 nm using a 590 nm emission ﬁlter). Rolling leukocytes
(cells/min) were deﬁned as white cells moving at a velocity
less than that of erythrocytes. Leukocytes were considered to
be adherent to the venular endothelium (100 μm) if they
remained stationary for 30 s or longer.
4.10. Ionized calcium-binding adapter molecule-1 (Iba-1)
immunohistochemistry
To study the activation of microglia activation it was used the
method of immunohistochemistry and quantiﬁcation of total
cells positive for Iba-1 (1:250, Wako Chemicals Inc., Rich-
mond, VA, USA). The animals were adequately anesthetized
and perfused via transcardiac route with 4% paraformalde-
hyde in 0.1 M phosphate buffer (0.1 M Na2PO4, 0.1 M NaHPO4
at pH 7.4). The brains were then removed and immersed in
b r a i n r e s e a r c h 1 5 7 8 ( 2 0 1 4 ) 4 9 – 5 9 57the same ﬁxative solution for 24 h and then transferred
to a solution of 30% sucrose. Cryostat-obtained 20-μm-thick
sections were collected in cryoprotectant solution. Selected
sections of frontal cortex were washed with PBS, incubated in
a blocking solution of 1% BSA for 2 h, followed by incubation
for 12 h with primary antibodies against Iba-1. After washing,
the sections were incubated for 1 h with biotinylated second-
ary antibody (1:1000; kit, Vector Labs, Burlingame, CA, USA).
Afterwards, tissues were subjected to incubation for 1 h with
AB complex (1:1000) and revealed with DAB (3,30-diamino-
benzidine). The sections were washed in PBS and mounted
on slides and coverslips with the aid of mounting
means Entelan. The images were analyzed with Zeiss Axio-
plan light microscope and computer software AxioVisions
4.8.1 (Carl Zeiss, Thornwood, NY, USA). Eight sections of the
frontal cortex of each animal were analyzed. Four represen-
tative areas of each section were photographed and cells
were quantiﬁed using ImageJs 1.6.0 (Wayne Rasband, NIH,
Bethesda, Maryland, USA).4.11. Determination of markers of oxidative stress
To indirectly assess the presence of oxidative stress in the
brain of TAA-treated mice lipid peroxidation and antioxidant
enzymes activity was measured. Superoxide Dismutase (SOD)
activity was measured according to Gao et al. (1998) based on
the capacity of SOD to inhibit pyrogallol autoxidation using a
spectrophotometer at 420 nm. The amount of SOD that
inhibited the oxidation of pyrogallol by 50% (relative to the
control) was deﬁned as a unit of SOD activity. Glutathione
Peroxidase (GSH-Px) activity was measured according to
Paglia and Valentine (1967) based on the capacity of GSH-Px
to oxidize NAD phosphate (NADPH). The consumption of
NADPH was accompanied by a decrease in absorbance
at 340 nm. Catalase activity of tissues was measured by
the method of Nelson and Kiesow (1972) in which the
disappearance of peroxide is followed spectrophotometrically
at 240 nm. The consumption of peroxide was accompanied by
a decrease in absorbance for 1 min and catalase was deﬁned
as the amount of enzyme which decomposed one mol of
peroxide been expressed in nmol min1 mg1 of protein.
The thiobarbituric acid reactive substances (TBARS) are mea-
sured as an index of malondialdehyde production and hence
lipid peroxidation by the method of Ohkawa et al. (1979). The
reaction product was determined by spectrophotometer at
532 nm.4.12. Statistical analysis
Statistical analysis was performed using one-way ANOVA,
with Tukey's post-test, and Student's t-test. P-values less
than 0.05 were considered statistically signiﬁcant. All data are
presented as mean7SEM.Conﬂict of interest
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